CJC-1295 wo DAC Growth Hormone Releasing Factor Analogue (no DAC)

CJC-1295 (without DAC) is a synthetic version of a signal molecule the brain naturally uses to trigger growth hormone release. Without the DAC (Drug Affinity Complex - a chemical attachment that makes some versions last much longer in the body), this compound produces a short, sharp pulse of growth hormone - more like the natural pattern the body uses.

CJC-1295 without DAC (wo DAC) is a 30-amino-acid synthetic analogue of Growth Hormone Releasing Hormone 1-29 (GHRH(1-29)) — the minimally active N-terminal fragment of endogenous GHRH responsible for receptor binding and GH secretion. It incorporates several amino acid substitutions compared to native GHRH(1-29) (sermorelin) that improve its enzymatic stability and receptor binding affinity. The designation “without DAC” (without Drug Affinity Complex) indicates the absence of a maleimidoproprionic acid (MPA) moiety that would otherwise allow covalent binding to circulating albumin for extended half-life — making CJC-1295 wo DAC a shorter-acting GHRH analogue compared to the DAC formulation.

Research on CJC-1295 wo DAC centres on growth hormone secretagogue biology — the study of compounds that stimulate growth hormone (GH) release from the anterior pituitary via the GHRH receptor (GHRHR). In preclinical animal models, GHRH analogues have been examined for their ability to stimulate pulsatile GH secretion and to examine the downstream effects on circulating IGF-1 (Insulin-like Growth Factor 1), which mediates many of GH’s anabolic and metabolic effects in peripheral tissues. The shorter half-life of CJC-1295 wo DAC makes it useful for studies requiring acute, defined GH stimulation windows rather than prolonged elevation.

As a research tool, CJC-1295 wo DAC is frequently used in studies examining GHRH receptor pharmacology, GH secretion dynamics, and pituitary function in rodent models. It is also studied alongside GHRP (growth hormone releasing peptide) compounds in combinatorial protocols, as GHRH receptor agonists and ghrelin receptor agonists act synergistically on somatotroph cells to amplify GH release. Velox Peptides supplies CJC-1295 wo DAC at 99.1% HPLC-verified purity as a lyophilised research reagent for in vitro use. Not for human or veterinary consumption.

Summary paraphrased from the peer-reviewed preclinical literature. For in vitro research use only. For source citations, email support@veloxpeps.com.

Every batch of CJC-1295 wo DAC is third-party HPLC-tested prior to dispatch. Batch documentation is available on request.

Previous batch CoAs are archived in the CoA library. For batch-specific CoA requests prior to purchase, contact support@veloxpeps.com.

CJC-1295 (no DAC) is sold by Velox Peptides (CRP Labs Ltd, UK company no. NI738125) and dispatched from the UK. Choose a vial size, pay on one page, and your order is dispatched the next working day.

• Delivery: Royal Mail Tracked 24 (1–2 working days, £5.99, free over £100) or Tracked 48 (2–3 working days, £3.80). See shipping.
• Payment: Pay by Bank through FCA-authorised open banking, or bank transfer. No card details needed.
• Testing: See the batch testing details above and past reports in the CoA library.
• Research use only: Supplied as a research reagent for in vitro use. Not for human or veterinary consumption. See our Research Use Policy.